Annual report [Section 13 and 15(d), not S-K Item 405]

Investment in account receivable (Tables)

v3.26.1
Investment in account receivable (Tables)
 12 Months Ended
Dec. 31, 2025
Receivables [Abstract]  
Schedule of receivables with imputed interest

The April 10, 2015 account receivable is supported by an exchange agreement and consisted of the following at December 31, 2025 and 2024:

 

    2025     2024  
Face value*   $ 287,200     $ 287,200  
Impairment**     (250,208 )     (250,208 )
Total     36,992       36,992  
Unamortized discount     (36,992 )     (36,992 )
Net balance     -       -  
Long term portion   $ -     $ -  

 

* Coincident with the June 11, 2024 impairment, accounts receivable of $2,300 were reclassified and concurrently impaired. Prior to the full impairment, the Company reduced the face value of its investment in account receivable by an additional $100 per month for five receivable payment installments.
**  

Impairment as recordation of expected credit loss.